City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...
Although real progress has been made in managing depression over recent decades, significant hurdles remain. In fact, around ...
The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...
"Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment," said ...
The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results